AKT1 and hepatocellular carcinoma: The MUC15/c-Met/PI3K/AKT/SOX2 axis determines the responses of hepatoma cells to lenvatinib treatment, as supported by the observation that MUC15 overexpression abrogates lenvatinib resistance [160].